This study investigates the efficacy of senolytic drugs in reducing seizures associated with neurodevelopmental disorders linked to hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. The research focuses on eliminating senescent-like cells that contribute to epileptogenesis in mTOR-related epilepsy models.
Administration of senolytic drugs selectively eliminated senescent-like cells in the brain, resulting in a significant reduction in seizure frequency and severity. These findings suggest that targeting pathological senescent-like cells can mitigate epileptic activity in mTOR-related neurodevelopmental disorders.
The study utilized a genetically engineered mouse model with hyperactivation of the mTOR pathway, developed in collaboration with genOway. This model harbors a conditional Knockout of the Tsc1 gene in neuronal populations, leading to mTOR pathway dysregulation and subsequent epilepsy phenotypes.
Epilepsy, Neurodevelopmental disorders, mTOR pathway, Senolytic therapy, Tuberous sclerosis complex
Conditional Knockout, Neuron-specific deletion, mTOR hyperactivation model, Senescence marker analysis, Pharmacological intervention
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
